Table 1.
Demographics and clinical characteristics.
| Multiple Sclerosis, n=58 | Healthy controls, n=50 | |
|---|---|---|
| Sex (female); n (%) | 44 (76%) | 34 (68%) |
| Age; y | 34 (27-40) | 33 (28-39) |
| BMI; kg/m2 | 23 (21-26) | 24 (22-26) |
| Current smoker; n (%) | 9 (16%) | 10 (20%) |
| Supplementation of probiotics; n (%) | 5 (9%) | 3 (6%) |
| Vegetarian/vegan/pescatarian diet; n (%) | 8 (15%) a | 5 (10%) |
| Disease duration (years since 1st symptom) | 0.8 (0.3-2.0) | N.A. |
| EDSS | 2.0 (1.0-3.0) | N.A. |
| No. of clinical relapses 1 year before baseline | 1 (1-2) | N.A. |
| Presence of clinical relapses 1 year prior baseline; n (%) | 57 (98%) | N.A. |
| T2 lesion count; n (%) | ||
| 1-9 | 16 (27.6%) | N.A |
| 10-19 | 9 (15.5%) | N.A |
| ≥20 | 33 (56.9%) | N.A |
| Gd + lesion count | 0 (0-1) | N.A. |
| Presence of Gd + lesions; n (%) | 21 (40%)b | N.A. |
All data is given in median with interquartile range except if otherwise specified. BMI, body mass index; EDSS, expanded disability status scale; No., number; Gd+, gadolinium enhancing; N.A., not applicable.
a
5 patients did not answer dietary questionnaire.
b
5 patients did not receive gadolinium-infusion at baseline MRI.